Biodesix, Inc. (BDSX) Dividend History

Company News

• Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

  Biodesix, a diagnostic solutions company, announced that new data from two studies will be presented at upcoming conferences. The studies highlight challenges in managing lung nodules and the potential of Biodesix's tests to guide clinical decision-making.

  GlobeNewswire Inc.
• Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

  Biodesix, a leading diagnostic solutions company, announced its financial results for the first quarter of 2025 and will host a conference call to discuss the results and provide a business update.

  GlobeNewswire Inc.
• Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

  Biodesix and Bio-Rad Laboratories contributed to research findings from Friends of Cancer Research's ctMoniTR Project, published in Clinical Cancer Research. The findings demonstrate a strong association between changes in circulating tumor DNA (ctDNA) levels and treatment outcomes, offering potential for integration of ctDNA analysis in therapeutic development and clinical cancer care.

  GlobeNewswire Inc.

  Featured Companies: BIO BIO.B
• Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

  Biodesix reported strong financial results for fiscal year 2024, with total revenue of $71.3 million, a 45% increase over the previous year, and gross margins of 78%. The company expects continued growth in 2025, with revenue guidance of $92-95 million.

  GlobeNewswire Inc.
• Biodesix to Present at TD Cowen 45th Annual Health Care Conference

  Biodesix, a leading diagnostic solutions company, announced that its CEO and CFO will present at the upcoming TD Cowen 45th Annual Health Care Conference on March 5, 2025.

  GlobeNewswire Inc.